a possible outcome would be an approval of mild dx and perhaps the fda orders another trial for the moderates....so the share price only goes to 500 bucks
If they don't, it seems likely they will fail top line results. Where it goes with the subgroup of mild patients is anyone's guess. They'll still have 500 or more in the mild groups to judge from but still will be viewed a failure by the usual suspects. I think Remi needs to make the market aware of the situation and any remedies the company may try to take involving recruitment at some point.
Market Data 
Markets 
AI
